About NewLimit
NewLimit is a Healthcare company based in San Francisco (United States) founded in 2022 by Jacob Kimmel, Brian Armstrong, and Blake Byers. NewLimit has raised $682.25 million across 4 funding rounds from investors including Lilly, Kleiner Perkins and Khosla Ventures. The company has 65 employees. NewLimit was last valued at $3.1 billion in June 2026. Its website newlimit.com draws about 20 thousand monthly visits. NewLimit offers products and services including Epigenetic Reprogramming Medicines, Immune System Rejuvenation Program, and Liver Function Restoration Program. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its competitors include Crown Bioscience, Alloy Therapeutics and NIH; 2 of its 3 listed competitors have raised funding.
Company details
Developer of epigenetic reprogramming medicines for aging-related diseases and healthspan extension. It focuses on restoring youthful function in old cells by reprogramming the epigenome. The company leverages technologies like single-cell genomics, machine learning, and high-throughput functional assays to identify epigenetic features of aging and discover interventions for rejuvenation. Its initial programs target the aging liver, immune, and vascular systems, with the long-term goal of significantly extending human healthspan through medicines for diseases associated with aging.
- Headquarters San Francisco, United States
- Employees 65
- Founders Jacob Kimmel, Brian Armstrong, Blake Byers
- Stage Unicorn
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website newlimit.com
- Social LinkedIn X
- Total Equity Funding$682.25M (USD)
in 4 rounds
- Latest Funding Round$435M (USD), Series C
Jun 2026
- InvestorsLilly
& 25 more
- Employee Count65
Products & Services of NewLimit
NewLimit offers a comprehensive portfolio of products and services, including Epigenetic Reprogramming Medicines, Immune System Rejuvenation Program, and Liver Function Restoration Program.
Medicines that restore youthful function in aging cells via reprogramming.
Program targeting aging immune systems for functional restoration.
Interventions to rejuvenate liver cells in aging processes.
Funding Insights of NewLimit
NewLimit has successfully raised a total of $682.25M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $435 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $682.25M
- Total Rounds 4
- Last Round Series C — $435M
- First Round $72.25M
(May 2023)
- Investors Count 26
All 4 funding rounds of NewLimit with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2026 | $435M | Series C | – | Founders Fund | |
| Oct 2025 | $45M | Series B | – | Lilly | – |
| May 2025 | $130M | Series B | – | Kleiner Perkins | |
| May 2023 | $72.25M | Series A | – | – |
| Date | Valuation | Stage |
|---|
Full valuation and stage history of NewLimit
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $3.1B (Jun 2026). 26 investors in total: 18 institutional and 8 angel.
Investors in NewLimit
NewLimit has secured backing from 26 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Lilly, Kleiner Perkins and Khosla Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments in technology and defense sectors. | foundersfund.com | |||
Venture capital firm investing in early-stage tech startups | 1972 | kleinerperkins.com | Menlo Park, United States | |
Early-stage startups are funded by this venture capital firm. | 2004 | khoslaventures.com | Menlo Park, United States | |
Venture capital investments are directed toward multiple sectors. | human.capital | San Francisco, United States | ||
Private equity firm | valorep.com | Chicago, United States | ||
Early-stage technology startups are invested in by Thrive Capital. | thrivecap.com | New York, United States | ||
Tech-enabled businesses are funded by Greenoaks venture capital firm. | greenoaks.com | San Francisco, United States | ||
Investments are managed by Quiet Capital in New York. | quiet.com | New York, United States | ||
Investing in Deep Tech and emerging technologies for 12 years. | boost.vc | |||
Venture capital investments are provided by Kivu Ventures. | kivu.vc |
Investor details for NewLimit
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NewLimit
4 people are tracked at NewLimit (4 in leadership); the tracked headcount is 65.
| Name | Role | Group |
|---|---|---|
Jacob Kimmel | Co-Founder | Leadership |
Brian Armstrong | Co-Founder | Leadership |
Blake Byers | Co-Founder | Leadership |
Alex Kim | Head Of Talent Acquisition | Leadership |
Complete people profiles for NewLimit
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of NewLimit
5 dated milestones of NewLimit across 4 years, from founding to its latest funding, stage changes and deals.
- Founded NewLimit is founded.
- Funding First funding round of $72.2M.
- Milestone Reaches Soonicorn status.
- Milestone Reaches Unicorn status.
- Funding Latest funding round, Series C, of $435.0M.
Competitors of NewLimit
NewLimit has 3 listed competitors in our database, 2 of them funded. They include Crown Bioscience, Alloy Therapeutics and NIH.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| crownbio.com | 2006 | Santa Clara, United States | $85.87M | 18 | Cancer and CVMD drugs are developed using PDX models. | |
| alloytx.com | 2017 | Lexington, United States | $157M | Drug discovery services are provided for therapeutic development. | ||
| nih.gov | 1887 | United States | Drug discovery services are provided to the biopharma sector. |
Detailed competitors of NewLimit
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of NewLimit
The website of NewLimit (newlimit.com) receives about 19.8K visits a month and ranks #1,905,996 among all websites worldwide, #2,603 in Biotechnology and Pharmaceuticals.
- Monthly visits19.8K
▲ 40.2% vs previous month
- Unique visitors5.5K
per month
- Global rank#1,905,996
among all websites
- Category rank#2,603
Health · Biotechnology and Pharmaceuticals
- Bounce rate51%
- Pages per visit1.7
- Average visit48 sec
- DevicesDesktop 53% · Mobile 47%
Websites whose visitors overlap most with NewLimit. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
google.com.br | google.com.br | 100% | #203 | – | |
| linkedin.com | 69% | 1.9B | #18 | View details |
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as NewLimit (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Newlimit
Complete news archive for NewLimit
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NewLimit
NewLimit was founded in 2022 and raised its 1st funding round 1 year after it was founded.
NewLimit is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
NewLimit is a funded company, having raised a total of $682.25M across 4 funding rounds to date. The company's 1st funding round was a Series A of $72.25M, raised on May 2023.
NewLimit has 65 employees.
Developer of epigenetic reprogramming medicines for aging-related diseases and healthspan extension. It focuses on restoring youthful function in old cells by reprogramming the epigenome. The company leverages technologies like single-cell genomics, machine learning, and high-throughput functional assays to identify epigenetic features of aging and discover interventions for rejuvenation. Its initial programs target the aging liver, immune, and vascular systems, with the long-term goal of significantly extending human healthspan through medicines for diseases associated with aging.
NewLimit's top competitors include Crown Bioscience, NIH and Alloy Therapeutics.
NewLimit offers Epigenetic Reprogramming Medicines, Immune System Rejuvenation Program, and Liver Function Restoration Program.
NewLimit has 26 investors. Key investors include Lilly, Kleiner Perkins, Khosla Ventures, Abstract, and Dimension Venture Partners.
The valuation of NewLimit is $3.1B as of Jun 2026.